Efficacy of Tizanidine (0.1 mg/Kg/HS) Versus Zolpidem 10 mg HS in Primary Insomnia: Double Blind Randomized Controlled Trial
试验速览
- 阶段
- 4 期
- 状态
- 尚未招募
- 入组人数
- 90
- 主要终点
- Pittsburgh Sleep Quality Index
研究概览
简要总结
The study's primary objective is to evaluate the effectiveness of Tinazidine compared to Zolpidem in enhancing sleep quality, with secondary objectives including the assessment of adverse effects, safety profile, and patient tolerance with each treatment. The trial will be conducted as a double-blind RCT, with participants randomly assigned to receive either Tinazidine (0.1 mg/Kg/HS) or Zolpidem 10 mg HS, for 12 weeks. Eligible participants, aged 18-60 years, diagnosed with primary insomnia as per DSM-5 criteria, will be recruited from an outpatient sleep clinic affiliated with Al-Masara Hospital. Data on sleep quality, and side effects, will be collected using the Sleep Pittsburgh Sleep Quality Index (PSQI), Clinical Global Impression (CGI), sleep diaries, actigraphy, polysomnography, and regular clinical interview though OPD follow-up visits. The primary outcome considered was the mean global PSQI score before and after the treatment. The primary outcome will be measured four times (baseline, 4 weeks, 8 weeks, and 12 weeks), We considered an attrition rate (dropout/lost follow-up) of 10%. Therefore, the sample size is 90 subjects (45 in each group). Group comparisons for mean scores will be conducted using independent samples t-tests, and within-group comparisons will be assessed using paired samples t-tests. Changes in sleep quality over time between treatment groups will be evaluated using repeated measures ANOVA. Associations between categorical variables will be examined using Chi-square tests (including Fisher's exact or Likelihood ratio tests as appropriate). Statistical significance will be considered for p-values less than 0.05. All analyses will be performed using IBM SPSS Statistics (Version 29.0). The findings of this study seek to elucidate the comparative efficacy and safety profiles of Tizanidine and Zolpidem in treating primary insomnia. The study aims to offer insights into the effectiveness of Tizanidine versus Zolpidem in improving sleep quality among patients with primary insomnia. Through the evaluation of efficacy, adverse effects, and safety profiles. This study aims to inform clinicians and healthcare practitioners about the optimal treatment choices for individuals with primary insomnia.
详细描述
Efficacy of Tizanidine (0.1 mg/Kg/HS) versus Zolpidem 10 mg HS in Primary Insomnia: Double Blind Randomized Controlled Trial
Literature review:
Insomnia: Prevalence and Impact
Around 10% of adults have an insomnia disorder, while another 20% experience occasional insomnia symptoms (1). Women, older adults, and those facing socioeconomic challenges are more prone to insomnia. Insomnia often persists over time, with a 40% persistence rate over five years (1). Insomnia is a significant public health concern requiring individual clinical care and broad population-level interventions to improve sleep health (1).
The Individual and Public Health Ramifications of Insomnia
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 60 Years(Adult)
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age and Gender Adult participants of either gender, aged 18-60 years old.
- •Diagnosis: Diagnosed with primary insomnia by a psychiatry specialist, based on DSM-5 criteria.
- •Consent: Able to provide written informed consent.
- •Compliance: Willing to comply with study procedures and follow-up assessments.
- •Medical Clearance: Participants must undergo a medical checkup by a medical officer affiliated with Al-Masarah Hospital before the randomization process. This checkup includes:
- •Medical history review.
- •Physical examination, including ECG.
- •Vital signs check.
- •Random blood sugar test.
- •Laboratory evaluation (CBC, LFT, RFT, TFT, Lipid profile).
- •Enrollment: Receiving medical clearance for enrollment in the study.
排除标准
- •Secondary Insomnia: Individuals diagnosed with secondary insomnia.
- •Substance Abuse History: Those with a history of substance abuse.
- •Significant Medical or Psychiatric Disorders: Individuals diagnosed with significant and/or unstable medical or psychiatric disorders or mental retardation.
- •Pregnancy or Lactation: Pregnant or lactating mothers, or those of childbearing potential not using an adequate method of contraception (excluding natural birth spacing methods).
- •Drug Allergy: Known hypersensitivity or allergy to Tinazidine or Benzodiazepines.
- •Communication Barriers: Individuals unable to understand or communicate with researchers.
- •Recent Participation in Clinical Trials: Those who have participated in other clinical trials involving investigational drugs within the past 30 days before participation.
- •Recent Use of Sleep Medication: Participants must not have taken any over-the-counter or prescription sleep medication within the past 30 days before participation.
- •Use of Substances Affecting CNS: No intake of any substance with central nervous system (CNS) effects known to affect sleep within 30 days before participation.
研究组 & 干预措施
Tizanidine Group
Participants will be asked to ingest Tinazidine, orally at home immediately before going to bed to sleep. Initially, the patients will be asked to ingest 2 mg HS, and it will be titrated up by 2 mg every 4 days, as per response and tolerability, up to a maximum dose of 0.1 mg/kg/HS.
干预措施: Tizanidine Hcl 4Mg Tab (Drug)
Zolpidem Group
Participants will be asked to ingest Zolpidem 10 mg HS, orally at home before bedtime.
干预措施: Zolpidem Tartrate 10 mg (Drug)
结局指标
主要结局
Pittsburgh Sleep Quality Index
时间窗: Baseline, 4 weeks, 8 weeks, 12 weeks
Total Items: The PSQI contains a total of 24 questions. Range of Component Scores: Each component score ranges from 0 to 3 points. A score of 0 indicates no difficulty. A score of 3 indicates severe difficulty. Global PSQI Score: The seven component scores are summed to yield one "global" score. Range: The global score ranges from 0 to 21 points. A global score of 0 suggests no difficulty in any areas. A global score of 21 suggests severe difficulties in all areas. Interpretation of the Global Score: The global PSQI score is used to evaluate an individual's sleep quality. A global score greater than 5 often indicates significant sleep disturbances or poor sleep quality.
次要结局
- Frequency and Severity of Side Effects(4 weeks, 8 weeks, 12 weeks)
研究者
Mohammed Al Alawi
Dr Mohmmed Al Alawi Bsc, MD,PhD, MRCPsych, OMSBPsych, ARABPsych
Sultan Qaboos University
